Published online May 2, 2005
PEDIATRICS Vol. 115 No. 5 May 2005, pp. 1320-1324 (doi:10.1542/peds.2004-1439)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alemzadeh, R.
Right arrow Articles by Wyatt, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alemzadeh, R.
Right arrow Articles by Wyatt, D. T.
Related Collections
Right arrow Endocrinology

Flexible Insulin Therapy With Glargine Insulin Improved Glycemic Control and Reduced Severe Hypoglycemia Among Preschool-Aged Children With Type 1 Diabetes Mellitus

Ramin Alemzadeh, MD, Tseghai Berhe, MD and David T. Wyatt, MD

From the Department of Pediatrics, Medical College of Wisconsin, Children's Research Institute, Milwaukee, Wisconsin

Background and Objectives. Insulin replacement regimens now stress the importance of administering throughout the day insulin doses that are based on flexible food choices and focusing on improved metabolic control. A flexible multiple daily insulin (FMDI) regimen (premeal lispro plus bedtime glargine) results in lower hemoglobin A1c (HbA1c) levels and fewer hypoglycemic episodes than does a multiple daily insulin (MDI) regimen among school-aged children and adolescents with type 1 diabetes mellitus (DM). The purpose of this study was to determine the feasibility of FMDI therapy for a group of preschool-aged children with type 1 DM who were transitioned from MDI therapy (premeal lispro plus ultralente insulin twice per day), by comparing BMI, total daily insulin requirements, HbA1c levels, and episodes of severe hypoglycemia.

Research Design and Methods. Data were collected over a 2-year period, during quarterly DM clinic visits, from 35 patients (17 female patients and 18 male patients, 4.8 ± 1.0 years of age) who had received MDI insulin therapy for ≥1 year before being transitioned to a FMDI regimen.

Results. Although there was no significant change in BMI with FMDI therapy (17.1 ± 1.8 kg/m2 vs 17.0 ± 1.7 kg/m2), 43% of patients (6 female subjects and 9 male subjects) were overweight (BMI of >85th percentile for age) both before and after treatment. The total daily insulin requirement (0.67 ± 0.13 U/kg per day vs 0.78 ± 0.14 U/kg per day) and bolus/basal insulin ratio (1.1 ± 0.4 vs 1.9 ± 0.6) were significantly increased and overall glycemic control was improved after transition to FMDI therapy (HbA1c levels: 8.8 ± 0.9% vs 8.3 ± 0.8%). However, HbA1c levels improved only among normal-weight subjects (9.0 ± 1.0% vs 8.3 ± 1.0%) and not among overweight subjects (8.7 ± 0.7% vs 8.4 ± 0.6%) after FMDI therapy. The overall rate of severe hypoglycemia was significantly decreased with the FMDI regimen (25.5 events per 100 patient-years vs 10.6 events per 100 patient-years) but again only for normal-weight children (29.7 events per 100 patient-years vs 7.4 events per 100 patient-years).

Conclusions. The use of FMDI therapy with glargine among preschool-aged children with type 1 DM was associated with improved overall glycemic control and decreased frequency of severe hypoglycemia. Although our study did not have a control group, these findings suggest that FMDI regimens may be a feasible therapeutic alternative to MDI treatment for preschool-aged children with type 1 DM. However, excess body weight status appeared to preclude a desirable therapeutic response in this group of patients.

Key Words: glargine • hemoglobin A1c • hypoglycemia • BMI • type 1 diabetes

Abbreviations: DM, diabetes mellitus • FMDI, flexible multiple daily insulin • MDI, multiple daily insulin • HbA1c, hemoglobin A1c • ICR, insulin/carbohydrate ratio • TDD, total daily dose • BG, blood glucose

Accepted Sep 20, 2004.




This article has been cited by other articles:


Home page
 Diabetes Spectr.Home page
L. C. Deeb
Diabetes Technology During the Past 30 Years: A Lot of Changes and Mostly for the Better
Diabetes Spectr, April 1, 2008; 21(2): 78 - 83.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
T. Danne, K. Lange, and O. Kordonouri
New developments in the treatment of type 1 diabetes in children
Arch. Dis. Child., November 1, 2007; 92(11): 1015 - 1019.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
V. Cherubini, A. Iannilli, D. Iafusco, F. Cardella, M. S. Giamprini, C. Fanelli, and G. V. Coppa
Premeal Insulin Treatment During Basal-Bolus Regimen in Young Children With Type 1 Diabetes
Diabetes Care, October 1, 2006; 29(10): 2311 - 2312.
[Full Text] [PDF]

Home page
 PediatricsHome page
T. Berhe, D. Postellon, B. Wilson, and R. Stone
Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: a retrospective study.
Pediatrics, June 1, 2006; 117(6): 2132 - 2137.
[Abstract] [Full Text] [PDF]